Sign in

You're signed outSign in or to get full access.

Cory William Kasimov

Cory William Kasimov

Senior Managing Director and fundamental research analyst at Evercore

New York, NY, US

Cory William Kasimov is a Senior Managing Director and fundamental research analyst at Evercore ISI, specializing in coverage of mid- and small-cap biotech companies, with a primary focus on the healthcare and medical sectors. He covers over 47 publicly traded biopharmaceutical and biotech companies, including names such as BioCryst, ImmunoGen, and Arena Pharmaceuticals, and has achieved a 55% success rate and an average return of 17.6% per recommendation according to TipRanks, consistently ranking in the top tiers of Wall Street analysts. Kasimov began his analyst career over two decades ago, with prior senior roles at J.P. Morgan for more than 15 years and positions at Oppenheimer, before joining Evercore in 2023. He holds an MBA in finance and marketing and an MPH in health systems management from Tulane University, as well as a BS in cellular and molecular biology, and is recognized for his regular top-3 placements in Institutional Investor’s All-America Research survey.

Cory William Kasimov's questions to Moderna (MRNA) leadership

Question · Q3 2025

Cory William Kasimov (Evercore) questioned whether the slow case accruals in Moderna's norovirus program were surprising or anticipated, and if this reflects on the commercial opportunity or potential demand for the product.

Answer

President Stephen Hoge stated that predicting norovirus epidemiology is still an early space, and the study was always designed with a potential for two seasons, which is now necessary. He expressed hope that the second season of enrollment would accrue enough cases for the interim analysis and affirmed that the commercial target product profile remains unchanged, emphasizing the well-established global burden of disease.

Ask follow-up questions

Fintool

Fintool can predict Moderna logo MRNA's earnings beat/miss a week before the call

Question · Q3 2025

Cory William Kasimov asked if Moderna was surprised by the slow case accruals in the norovirus program and if this offers any reflection on the commercial opportunity or potential demand for the product should it be approved.

Answer

Stephen Hoge, President, stated that the norovirus study was always designed as a potential two-season study, and slow case accrual is not uncommon in vaccine trials. He expressed hope that the second season of enrollment would accrue sufficient cases for the interim analysis. He affirmed that the commercial target product profile remains unchanged, emphasizing the well-established global burden of norovirus disease and the potential health economic benefit of prevention.

Ask follow-up questions

Fintool

Fintool can write a report on Moderna logo MRNA's next earnings in your company's style and formatting